Person:
GÜRSOY, VİLDAN

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

Job Title

Last Name

GÜRSOY

First Name

VİLDAN

Name

Filters

2015 - 201912020 - 20221
Reset filters

Settings

Search Results

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Publication
    Retrospective analysis of clinical efficacy of erlotinib in patients with non-small cell lung cancer
    (Derman Medical Publ, 2015-03-01) ÖZKAYA, GÜVEN; Ayyıldız, Aylin; Kanat, Özkan; DELİGÖNÜL, ADEM; Deligönül, Adem; Gürsoy, Vildan; GÜRSOY, VİLDAN; Bursa Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Onkoloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı.; 0000-0003-0297-846X; A-4421-2016
    Aim: In this study, we aimed to evaluate the efficacy and safety of erlotinib as second-, third-, and fourth-line treatment for Turkish patients with advanced non-small cell lung cancer (NSCLC). Material and Method: Thirty-nine patients with advanced, previously treated NSCLC who received 150 mg of erlotinib once daily orally until disease progression or intolerable toxicity were retrospectively analyzed. Results: We observed no complete response, partial responses were observed in 7 (17.9%) patients, and 16 (41 Ph) patients had stable disease. The median progression -free survival was 242 days (95% CI 51-224), and the median overall survival (OS) was 377 days (950/0 Cl 291462). The median 05 of females was significantly better than male patients (470 vs. 271 days, p=0.046). The treatment was generally well tolerated. The most common side effect was skin rash (4105). Discussion: Erlotinib was safe and effective in treating Turkish patients with advanced NSCLC who had been previously treated with the standard chemotherapy.
  • No Thumbnail Available
    Publication
    Efficacy of plerixafor plus g-csf in patients with multiple myeloma and lymphoma who have had mobilization failure with at least two regimens. a retrospective study
    (Springernature, 2022-11-01) Özkocaman, V.; ÖZKOCAMAN, VİLDAN; Pınar, İbrahim Ethem; PINAR, İBRAHİM ETHEM; Özkalemkas, Fahri; ÖZKALEMKAŞ, FAHİR; Ersal, Tuğba; ERSAL, TUBA; Buldu, Merve; BULDU, MERVE; Gürsoy,; GÜRSOY, VİLDAN; Bursa Uludağ Üniversitesi/Tıp Fakültesi.; 0000-0001-9907-1498; 0000-0002-0116-2082; JGM-6601-2023; M-1070-2014; JWP-2738-2024